SBIR/STTR Research Award

Inexpensive Genetic Detection of Infectious Organisms

Award identifier b1a081f337bbdb35b57e55dea3aac4e00f5b8cccf678861d0ef14d40ebf411c8Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$100,758

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ATOM SCIENCES, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (Applicant's abstract): The proposed project is aimed at developing a very inexpensive and rapid diagnostic test that can be used to identify specific infectious organisms. The goal is to make the cost so low that managed health organizations would encourage its regular use in clinical settings, thus greatly reducing prescriptions for antibiotics in cases where they are ineffective, and consequently reducing one source of antimicrobial-resistant strains of bacteria. The proposed diagnostic test is based upon DNA array technology, which can be designed to not only identify infectious pathogens but also determine if antimicrobial resistant bacteria strains are present. The unique feature of the proposed test is that it utilizes an electrical property that is very inexpensive to measure. The test is based on the fact that, under the appropriate conditions, the increase in effective dielectric thickness caused by binding a small amount of DNA to an insulating monolayer on a metal conductor will produce a significant, readily measurable change in measured capacitance. In Phase I, controlled tests are proposed to characterize the new technique and assess its likely effectiveness in a clinical setting. In Phase II, DNA array will be developed to detect common pathogens. PROPOSED COMMERCIAL APPLICATION: A low-cost DNA-based diagnostic test for infectious pathogens could be utilized in essentially every hospital and clinic in the world. As antimicrobial-resistant bacteria become more common, the need for such tests will gain widespread acceptance. We estimate that tens of millions of the arrays will eventually be used each year in U.S. hospitals alone.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.